Welcome to our dedicated page for Evolent Health SEC filings (Ticker: EVH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the financial heartbeat of Evolent Health’s value-based care model means wading through pages of risk-sharing metrics, medical loss ratios, and acquisition details. Whether you’re hunting for Evolent Health insider trading Form 4 transactions before a material announcement or trying to decode management’s discussion in the annual report, raw SEC feeds can feel impenetrable.
Stock Titan turns that fog into clarity. Our AI-powered summaries distill each Evolent Health quarterly earnings report 10-Q filing and every Evolent Health 8-K material events explained alert into plain English minutes after they hit EDGAR. Interactive dashboards flag Evolent Health Form 4 insider transactions real-time, link executive share sales to tables in the Evolent Health proxy statement executive compensation section, and compare specialty-care margins period over period. It’s the fastest path to Evolent Health SEC filings explained simply.
Need deeper context? The expert layer highlights how risk-bearing contracts affect revenue recognition, why oncology carve-outs appear in the footnotes, and how new AI partnerships flow through operating expenses. You’ll find Evolent Health annual report 10-K simplified, Evolent Health earnings report filing analysis, and guidance for understanding Evolent Health SEC documents with AI—all in one place. Save hours locating Evolent Health executive stock transactions Form 4 or reconciling cost trends, and make confident decisions with real-time, comprehensive coverage.
Schedule 13G filed for Evolent Health, Inc. (CUSIP 30050B101). The filing, dated for the event 06/30/2025 and signed 08/06/2025, reports beneficial ownership by Morgan Stanley entities.
- Morgan Stanley (parent) reports 8,210,410 shares beneficially owned, representing 7.0% of Class A common stock with 0 sole voting power, 8,202,877 shared voting power and 8,210,410 shared dispositive power.
- Morgan Stanley Capital Services LLC reports 6,776,898 shares ( 5.8% ) with 0 sole voting/dispositive power and 6,776,898 shared voting and dispositive power.
- Issuer principal executive offices listed at 1812 North Moore St, Suite 1705, Arlington, VA 22209.
The filing is made under Rule 13d-1(b)/(c)/(d) format as a Schedule 13G and includes exhibits (Joint Filing Agreement and Item 7 information).
Key takeaways from Evolent Health (EVH) Form 4
Chief Financial Officer John Paul Johnson was granted 25,461 Class A restricted stock units (RSUs) on 1 July 2025 under the company’s Amended and Restated 2015 Omnibus Incentive Compensation Plan. The award was made at no cost (Transaction Code “A”) and increases his directly held stake to 309,245 shares.
The RSUs vest on a back-loaded schedule: 34 % on 1 July 2026 and 33 % on each of 1 July 2027 and 1 July 2028. This tranche represents the second portion of the 2025 annual equity cycle; issuance was contingent on shareholder approval of additional plan shares received at the 5 June 2025 annual meeting.
No open-market purchases, derivative transactions or sales were disclosed, and no earnings or cash proceeds are involved. The filing is therefore routine incentive compensation that strengthens executive equity alignment but has minimal direct financial impact on near-term valuation.
Evolent Health (EVH) said on June 19, 2025 that oncology cost trends through May remain below its expectations, and the company reaffirmed full-year 2025 Adjusted EBITDA guidance of $135.0 million to $165.0 million and Q2 2025 Adjusted EBITDA guidance of $33.0 million to $40.0 million. The company stated it cannot meaningfully reconcile this non-GAAP guidance to net income because several significant reconciling items are not presently determinable. Separately, on June 19 the company and EVH LLC entered a Commitment Letter with Ares Management credit funds for an incremental debt facility to provide non-dilutive capital to retire its 2025 Convertible Notes by October 15, 2025 and to fund working capital, with a post-payoff cash target of no more than $125.0 million.
FAQ
What is the current stock price of Evolent Health (EVH)?
What is the market cap of Evolent Health (EVH)?
